680 related articles for article (PubMed ID: 23760587)
1. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
[TBL] [Abstract][Full Text] [Related]
3. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
4. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
[TBL] [Abstract][Full Text] [Related]
5. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
7. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.
An HJ; Ryu MH; Ryoo BY; Sohn BS; Kim KH; Oh ST; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2013 Dec; 20(13):4212-8. PubMed ID: 24052319
[TBL] [Abstract][Full Text] [Related]
8. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
9. Surgical management of rectal gastrointestinal stromal tumors.
Tielen R; Verhoef C; van Coevorden F; Reyners AK; van der Graaf WT; Bonenkamp JJ; van Etten B; de Wilt JH
J Surg Oncol; 2013 Mar; 107(4):320-3. PubMed ID: 22806955
[TBL] [Abstract][Full Text] [Related]
10. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A
Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
[TBL] [Abstract][Full Text] [Related]
12. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
Li SX; Li ZY; Zhang LH; Bu ZD; Wu AW; Wu XJ; Zong XL; Shan F; Ji X; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340
[TBL] [Abstract][Full Text] [Related]
13. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.
Machlenkin S; Pinsk I; Tulchinsky H; Ziv Y; Sayfan J; Duek D; Rabau M; Walfisch S
Colorectal Dis; 2011 Oct; 13(10):1110-5. PubMed ID: 21040362
[TBL] [Abstract][Full Text] [Related]
14. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
[TBL] [Abstract][Full Text] [Related]
16. [Prognosis analysis of 216 cases of gastrointestinal stromal tumor].
Liu LC; Xu WT
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar; 15(3):255-8. PubMed ID: 22454172
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
[TBL] [Abstract][Full Text] [Related]
18. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
19. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors.
Seshadri RA; Rajendranath R
J Cancer Res Ther; 2009; 5(4):267-71. PubMed ID: 20160360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
